nextSource Names David Savarise Chief Client Officer
Savarise to lead the Company’s commitment to exceptional custom workforce management solutions for client companies....
Globe Newswire6-03-2023, 21:49
Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26